Ultrahypofractionated linac-based radiotherapy of primary prostate cancer - early results of an Austrian nationwide registry study.

Authors

Natalee Annon-Eberharter, Johannes Berchtold, Angela Ginestet, Georg Gruber, Lukas Kocik, Oxana Komina, Tanja Langsenlehner, Elisabeth Nechvile, Christoph Resl, Falk Röder, Samuel M Vorbach, Ludmila Zahlbruckner, Frank Wolf

Published in

Clinical and translational radiation oncology. Volume 61. Pages 101242. Epub Jul 21, 2026.

Abstract

Ultrahypofractionated radiotherapy (UHFX) has emerged as an attractive alternative to normo- and moderately hypofractionated regimens for localized prostate cancer. However, its broader adoption remains limited by technical challenges and concerns regarding genitourinary toxicity. We established a nationwide Austrian registry of low and intermediate risk localized prostate cancer patients treated with linac-based stereotactic body radiation therapy (SBRT) to provide real-world data about UHFX treatment conventions, toxicity, oncologic outcomes, and patient-reported quality of life (QoL).
This is a multicenter, registry-based prospective study. Eligibility was restricted to patients with low- and intermediate-risk prostate cancer. Patient characteristics, toxicity (CTCAE v5.1), urinary function (IPSS), and QoL (EPIC-26) were prospectively reported in a web-based database.
Between September 2022 and April 2026, 191 patients were enrolled, of whom 169 were included in the final analysis. Median follow-up was 14 months (IQR 7-24). NCCN risk distribution consisted of 23.7% low-risk, 48.5% favorable intermediate-risk, and 27.8% unfavorable intermediate-risk disease. All patients received 40 Gy in five fractions. Treatment was delivered on alternating weekdays in 61.5% and on consecutive weekdays in 38.5% of patients. Median PSA declined from 7.74 ng/mL at baseline to 0.63 ng/mL at 12 months. No biochemical recurrence was observed during the first year of follow-up. Grade 1-2 genitourinary toxicity peaked at treatment completion and declined thereafter, while grade ≥ 3 toxicity remained uncommon (<1%). Gastrointestinal toxicity remained low throughout follow-up, with no grade ≥ 3 gastrointestinal toxicity observed.
In this nationwide real-world cohort, UHFX delivered in five fractions was well tolerated and showed favorable early oncological outcomes with low rates of severe toxicity across academic and non-academic institutions, consistent with results from randomized phase III trials.

PMID:
42621857
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.